Physician profile
Olivia E Peters
NPI 1841333432
$831.34
in general payments reported to CMS, 2019-2025
15 companies · $352 in 2025
The $352 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.94 · 2020: $83.50 · 2021: $68.05 · 2022: $12.56 · 2023: $53.91 · 2024: $164 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $206.26 | 2024-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $170.38 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $75.14 | 2019-2023 | M-M-R II, Vaxelis, Vaxneuvance |
| Pfizer INC. | $63.39 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $58.10 | 2019-2020 | |
| Sanofi Pasteur INC. | $50.13 | 2025 | |
| Neurelis, INC. | $44.80 | 2021 | |
| Cranial Technologies, INC | $34.28 | 2020-2021 | |
| Noven Therapeutics, LLC | $23.92 | 2024 | Xelstrym |
| Tris Pharma INC | $23.64 | 2019 | |
| Alk-Abello, INC | $23.00 | 2023 | Ragwitek, Grastek, Odactra |
| Sobi, INC | $18.84 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $13.98 | 2024 | Flumist Quadrivalent |
| Biomarin Pharmaceutical INC. | $13.80 | 2024 | Voxzogo 1.2mg |
| Takeda Pharmaceuticals U.S.A., INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.